SNCG and Parkinson disease: Manne and co-authors utilized monomeric recombinant human wild-type α-synuclein as a substrate to detect α-synuclein aggregates in CSF samples from PD and PSP patients, as well as post-mortem brain tissues from PD, DLB, and AD patients and healthy controls [76].